Catalyst
Slingshot members are tracking this event:
Tesaro (TSRO) Presents Phase 3 ENGOT-OV16/NOVA Data Evaluating Niraparib in Ovarian Cancer Regardless of BRCA Status
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TSRO |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Niraparib, Phase 3, Engot-ov16/nova, Ovarian Cancer, European Society For Medical Oncology 2016, Annual Meeting
